论文部分内容阅读
据62例慢性乙型肝炎分组治疗观察,治疗组HBV DNA阴转率33.3％,对照组为11.1％,HBeAg阴转率和抗-HBe阳转率分别为44.4％和33.3％,对照组分别为13.3％和10.0％。治疗结束后半年随访HBV DNA、HBeAg阴转率和抗-HBe阳转率分别为50.0％、55.6％和44.4％。故认为HBV特异性细胞毒T淋巴细胞治疗,对慢性乙型肝炎可获满意临床效果。
According to 62 cases of chronic hepatitis B treatment group, the treatment group, HBV DNA negative conversion rate of 33.3%, 11.1% in the control group, HBeAg negative conversion rate and anti-HBe positive conversion rates were 44.4% and 33.3%, respectively, the control group were 13.3% and 10.0%. Half-year follow-up of HBV DNA after treatment, HBeAg negative conversion rate and anti-HBe positive conversion rates were 50.0%, 55.6% and 44.4%. So that HBV-specific cytotoxic T lymphocyte therapy, chronic hepatitis B will be satisfied with the clinical effect.